ArticleDigestive diseases and sciences2008
Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms.
Article in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Prevalence and characteristics of bladder wall thickening in dogs without lower urinary tract disease: an ultrasonographic study.Frontiers in veterinary science · 2025Article
- Clinical Management of the Microbiome in Irritable Bowel Syndrome.Journal of the Canadian Association of Gastroenterology · 2021Article
- Small Intestinal Bacterial Overgrowth and Coronary Artery Disease: What Is in the CArDs?Digestive diseases and sciences · 2018Article
- Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.Gut and liver · 2017Review
- Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors.Journal of chiropractic humanities · 2016Review
- Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease.International neurourology journal · 2016Review
- Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.Global advances in health and medicine · 2014Article
- Association between irritable bowel syndrome and restless legs syndrome: a comparative study with control group.Journal of neurogastroenterology and motility · 2012Article
- Prevalence of restless legs syndrome in patients with irritable bowel syndrome.World journal of gastroenterology · 2011Article
- An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium.Gastroenterology & hepatology · 2010Article
- Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?Therapeutic advances in gastroenterology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInterstitial cystitis (IC) often coexists with irritable bowel syndrome (IBS). IBS may be explained by small-intestinal bacterial overgrowth (SIBO), which increases immune activation and visceral hypersensitivity. This prospective pilot study tested hypotheses that IC patients with gastrointestinal (GI) symptoms have SIBO, that nonabsorbable antibiotic use improves symptoms, and that improvement is sustained by prokinetic therapy.
methodsConsecutive IC patients with GI symptoms had lactulose breath testing (LBT). Those with abnormal results received rifaximin 1,200-1,800 mg/day for 10 days then tegaserod 3 mg/nightly. Questionnaires addressed IC and GI global improvement.
resultsOf 21 patients, 17 (81%) had abnormal LBTs. Of 15 patients treated, GI global improvement was moderate to great in 11 (73%) and sustained in ten (67%). IC global improvement was moderate to great in six (40%) and sustained in seven (47%).
conclusionsA majority of IC patients and GI symptoms had an abnormal LBT suggesting SIBO. Rifaximin improved symptoms, which was sustained by tegaserod.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.